Adalimumab for nail psoriasis: Efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial
Journal of the European Academy of Dermatology and Venereology | Sep 12, 2019
Most read this week
Journal of the European Academy of Dermatology and Venereology | Sep 12, 2019